Petri

GALY Inc. is a biotechnology company founded in 2019 and based in the United States, specializing in the production of cotton through cellular agriculture. Utilizing proprietary biomaterial technology, GALY creates cotton yarns in a laboratory setting, eliminating the need for traditional farming methods. This innovative approach produces high-quality cotton at a lower cost and with a reduced environmental impact compared to conventional cotton production. By supplying the textile industry with sustainable raw materials, GALY aims to provide clothing brands with eco-friendly alternatives to natural fabrics.

Modern Synthesis is a biomaterial company focused on creating sustainable textiles for the fashion industry through innovative microbial weaving techniques. By harnessing the capabilities of bacteria, the company develops a new class of biobased textiles that offer significant advantages over traditional materials. These textiles provide strength and durability without the use of harmful petrochemical binders or toxic byproducts, and they eliminate the need for animal inputs, allowing for a diverse range of aesthetics to meet designers' needs. Modern Synthesis' technology utilizes bacterial nanocellulose, a highly versatile and robust form of cellulose, to produce customizable bio-textiles and composites. This approach not only replaces conventional materials such as animal leathers and plastic-based synthetics but also integrates efficiently with existing manufacturing practices, promoting scalability and sustainability within the industry.

Minus is a beanless coffee company which produces coffee.

New Equilibrium Biosciences is focused on developing therapeutic drugs aimed at treating cancer and neurodegenerative diseases. The company employs a unique approach that integrates artificial intelligence with quantum chemistry to enhance biophysical experiments. This innovative platform specializes in the research and development of therapeutics that target intrinsically disordered proteins (IDPs), which are often implicated in various neurodegenerative disorders. By utilizing IDP-specific compound libraries, New Equilibrium Biosciences seeks to identify and exploit transient binding pockets on these proteins, facilitating the discovery of lead drug candidates. This approach aims to improve medical procedures and ultimately contribute to advancements in healthcare.

Yard Stick specializes in measuring soil carbon to support climate-friendly agricultural practices. By addressing significant measurement challenges, the company has developed an innovative handheld device that evaluates carbon stocks and changes in real-time using VisNIR spectrometry. This technology allows for accurate detection of organic carbon levels, significantly reducing the cost of soil carbon measurement by over 90%. As a result, Yard Stick aims to enhance the adoption of evidence-based regenerative practices, which can improve soil health, increase farmers' income, and contribute to combating climate change. Through its advancements, Yard Stick seeks to create opportunities for both scientists and farmers to effectively manage soil carbon, thus facilitating a more sustainable agricultural future.

Medsix is a company focused on improving the management of wound drains for patients undergoing complex surgeries or those with slow healing processes. Traditional methods of monitoring drain output rely on manual assessments by nurses or patients, which can lead to inaccuracies, resulting in prolonged drain use and missed early signs of complications such as infections or blockages. To address these issues, Medsix is developing a disposable sensor that can be attached to any wound drain, incorporating predictive analytics to automate monitoring. This innovation aims to enhance patient outcomes by facilitating earlier detection of complications and enabling timely removal of drains, thereby reducing recovery times. Additionally, it seeks to improve clinical workflows for healthcare providers and create standardized practices for wound drain management. For payers, the system is designed to decrease hospital stays and readmission rates, ultimately increasing reimbursement efficiencies.

GALY Inc. is a biotechnology company founded in 2019 and based in the United States, specializing in the production of cotton through cellular agriculture. Utilizing proprietary biomaterial technology, GALY creates cotton yarns in a laboratory setting, eliminating the need for traditional farming methods. This innovative approach produces high-quality cotton at a lower cost and with a reduced environmental impact compared to conventional cotton production. By supplying the textile industry with sustainable raw materials, GALY aims to provide clothing brands with eco-friendly alternatives to natural fabrics.

Matterworks is a developer of an artificial intelligence platform focused on advancing the field of metabolomics within the life sciences. The company's technology enhances analytical capabilities, allowing scientific researchers to conduct faster and more comprehensive metabolomic screenings. By facilitating the discovery and engineering processes, Matterworks aims to accelerate scientific progress and support innovation in various biological applications.

New Equilibrium Biosciences is focused on developing therapeutic drugs aimed at treating cancer and neurodegenerative diseases. The company employs a unique approach that integrates artificial intelligence with quantum chemistry to enhance biophysical experiments. This innovative platform specializes in the research and development of therapeutics that target intrinsically disordered proteins (IDPs), which are often implicated in various neurodegenerative disorders. By utilizing IDP-specific compound libraries, New Equilibrium Biosciences seeks to identify and exploit transient binding pockets on these proteins, facilitating the discovery of lead drug candidates. This approach aims to improve medical procedures and ultimately contribute to advancements in healthcare.